NCT03142022 Sleep-disordered Breathing After Solid Organ Transplantation
| NCT ID | NCT03142022 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Universitaire Ziekenhuizen KU Leuven |
| Condition | Lung Transplantation |
| Study Type | OBSERVATIONAL |
| Enrollment | 300 participants |
| Start Date | 2014-11 |
| Primary Completion | 2025-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 300 participants in total. It began in 2014-11 with a primary completion date of 2025-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Sleep-disordered breathing (SDB) describes a group of disorders in which partial or complete cessation of breathing occurs many times throughout the night, resulting in daytime sleepiness or fatigue that interferes with a person's ability to function and reduces quality of life. Transplantation has become an important treatment modality for end-stage organ failure. Transplant recipients are now living longer and, hence, develop chronic adverse medical conditions. Furthermore, transplantation is associated with weight gain. Despite the high prevalence of poor sleep and cardiovascular conditions among transplant patients, SDB is not well studied in these patients.
Eligibility Criteria
Inclusion Criteria: * Patients 1 year after lung transplantation Exclusion Criteria: * Refusal of PSG * Medical contra-indication to perform PSG
Contact & Investigator
Dries Testelmans, MD, PhD
PRINCIPAL INVESTIGATOR
UZ Leuven
Frequently Asked Questions
Who can join the NCT03142022 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Lung Transplantation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03142022 currently recruiting?
Yes, NCT03142022 is actively recruiting participants. Contact the research team at dries.testelmans@uzleuven.be for enrollment information.
Where is the NCT03142022 trial being conducted?
This trial is being conducted at Leuven, Belgium.
Who is sponsoring the NCT03142022 clinical trial?
NCT03142022 is sponsored by Universitaire Ziekenhuizen KU Leuven. The principal investigator is Dries Testelmans, MD, PhD at UZ Leuven. The trial plans to enroll 300 participants.